Resource Logo

Chronic active hepatitis B exacerbations in human immunodeficiency virus-infected patients following development of resistance to or withdrawal of lamivudine.


Clin Infect Dis. 1999 May;28(5):1032-5. Unique Identifier : AIDSLINE

Lamivudine is a nucleoside analog with activity against human immunodeficiency virus (HIV) and hepatitis B virus (HBV). Patients coinfected with HIV and HBV may have hepatitis flares when lamivudine therapy is discontinued or when resistance of HBV to lamivudine emerges. This retrospective, descriptive study conducted in three tertiary care medical centers describes patients coinfected with HIV type 1 and HBV who presented with a spectrum of clinical and subclinical hepatitic responses to lamivudine withdrawal or resistance. One patient had fulminant hepatic failure and a second patient had subclinical hepatitis when lamivudine therapy was discontinued and a more efficacious antiretroviral regimen was substituted. Three patients had flares of hepatitis after 13 to 18 months of lamivudine therapy. Lamivudine withdrawal or emergence of lamivudine-resistant mutants in patients coinfected with HIV and HBV may result in severe hepatitis. Clinicians caring for patients with coinfection with HIV and HBV should be aware of the possibility that a hepatitis B flare may occur in previously asymptomatic carrier patients.

JOURNAL ARTICLE Adult Anti-HIV Agents/*THERAPEUTIC USE AIDS-Related Opportunistic Infections/BLOOD/*DRUG THERAPY Case Report Drug Resistance Hepatitis B e Antigens Hepatitis B, Chronic/BLOOD/*DRUG THERAPY/ETIOLOGY Human HIV Infections/BLOOD/*DRUG THERAPY *HIV-1 Lamivudine/*THERAPEUTIC USE Male Middle Age Recurrence Retrospective Studies Treatment Failure


Information in this article was accurate in December 30, 1999. The state of the art may have changed since the publication date. This material is designed to support, not replace, the relationship that exists between you and your doctor. Always discuss treatment options with a doctor who specializes in treating HIV.